PortalPublikationenCost effectiveness analysis of immunotherapy in patients wit...

Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany.

Standard

Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. / Westerhout, K Y; Verheggen, B G; Schreder, C H; Augustin, Matthias.

in: J MED ECON, Jahrgang 15, Nr. 5, 5, 2012, S. 906-917.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Westerhout, KY, Verheggen, BG, Schreder, CH & Augustin, M 2012, 'Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany.', J MED ECON, Jg. 15, Nr. 5, 5, S. 906-917. <http://www.ncbi.nlm.nih.gov/pubmed/22533527?dopt=Citation>

APA

Westerhout, K. Y., Verheggen, B. G., Schreder, C. H., & Augustin, M. (2012). Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J MED ECON, 15(5), 906-917. [5]. http://www.ncbi.nlm.nih.gov/pubmed/22533527?dopt=Citation

Vancouver

Westerhout KY, Verheggen BG, Schreder CH, Augustin M. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J MED ECON. 2012;15(5):906-917. 5.

Bibtex

@article{9aadcd203c544dafa16790a060ed540a,
title = "Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany.",
abstract = "An economic evaluation was conducted to assess the outcomes and costs as well as cost-effectiveness of the following grass-pollen immunotherapies: OA (Oralair; Stallergenes S.A., Antony, France) vs GRZ (Grazax; ALK-Abell{\'o}, H{\o}rsholm, Denmark), and ALD (Alk Depot SQ; ALK-Abell{\'o}) (immunotherapy agents alongside symptomatic medication) and symptomatic treatment alone for grass pollen allergic rhinoconjunctivitis.",
keywords = "Adult, Germany, Humans, Cost-Benefit Analysis, Treatment Outcome, Antigens, Plant/immunology, Desensitization, Immunologic/*economics, Poaceae/*adverse effects/immunology, Pollen/adverse effects/*immunology, Quality-Adjusted Life Years, Rhinitis, Allergic, Seasonal/*drug therapy/immunology, Adult, Germany, Humans, Cost-Benefit Analysis, Treatment Outcome, Antigens, Plant/immunology, Desensitization, Immunologic/*economics, Poaceae/*adverse effects/immunology, Pollen/adverse effects/*immunology, Quality-Adjusted Life Years, Rhinitis, Allergic, Seasonal/*drug therapy/immunology",
author = "Westerhout, {K Y} and Verheggen, {B G} and Schreder, {C H} and Matthias Augustin",
year = "2012",
language = "English",
volume = "15",
pages = "906--917",
journal = "J MED ECON",
issn = "1369-6998",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

RIS

TY - JOUR

T1 - Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany.

AU - Westerhout, K Y

AU - Verheggen, B G

AU - Schreder, C H

AU - Augustin, Matthias

PY - 2012

Y1 - 2012

N2 - An economic evaluation was conducted to assess the outcomes and costs as well as cost-effectiveness of the following grass-pollen immunotherapies: OA (Oralair; Stallergenes S.A., Antony, France) vs GRZ (Grazax; ALK-Abelló, Hørsholm, Denmark), and ALD (Alk Depot SQ; ALK-Abelló) (immunotherapy agents alongside symptomatic medication) and symptomatic treatment alone for grass pollen allergic rhinoconjunctivitis.

AB - An economic evaluation was conducted to assess the outcomes and costs as well as cost-effectiveness of the following grass-pollen immunotherapies: OA (Oralair; Stallergenes S.A., Antony, France) vs GRZ (Grazax; ALK-Abelló, Hørsholm, Denmark), and ALD (Alk Depot SQ; ALK-Abelló) (immunotherapy agents alongside symptomatic medication) and symptomatic treatment alone for grass pollen allergic rhinoconjunctivitis.

KW - Adult

KW - Germany

KW - Humans

KW - Cost-Benefit Analysis

KW - Treatment Outcome

KW - Antigens, Plant/immunology

KW - Desensitization, Immunologic/economics

KW - Poaceae/adverse effects/immunology

KW - Pollen/adverse effects/immunology

KW - Quality-Adjusted Life Years

KW - Rhinitis, Allergic, Seasonal/drug therapy/immunology

KW - Adult

KW - Germany

KW - Humans

KW - Cost-Benefit Analysis

KW - Treatment Outcome

KW - Antigens, Plant/immunology

KW - Desensitization, Immunologic/economics

KW - Poaceae/adverse effects/immunology

KW - Pollen/adverse effects/immunology

KW - Quality-Adjusted Life Years

KW - Rhinitis, Allergic, Seasonal/drug therapy/immunology

M3 - SCORING: Journal article

VL - 15

SP - 906

EP - 917

JO - J MED ECON

JF - J MED ECON

SN - 1369-6998

IS - 5

M1 - 5

ER -